Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 target-engagement study in MDD patients on an SSRI, evaluating the effects of EVX-301 on levels of serotonin and its main metabolite (5-HIAA) in the cerebrospinal fluid (CSF)

Next Previous
Trial Profile

A Phase 1 target-engagement study in MDD patients on an SSRI, evaluating the effects of EVX-301 on levels of serotonin and its main metabolite (5-HIAA) in the cerebrospinal fluid (CSF)

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 06 Nov 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Oxitriptan (Primary)
  • Indications Major depressive disorder
  • Focus Adverse reactions

Most Recent Events

  • 06 Nov 2025 New trial record
  • 22 Sep 2025 According to the Evecxia Media Release, company plans to conduct a Phase 1 target-engagement study in MDD patients on an SSRI, with Patient enrollment in this Study is expected to start in Q4'25 with topline results anticipated in Q1'26.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top